IRLAB Therapeutics, a biotech focused on pioneering treatments for Parkinson’s disease, has announced a new collaboration with Danish biotech Biomia to evaluate Biomia’s drug candidates using IRLAB’s Integrative Screening Process (ISP).

 

“We are excited to enter into an ISP-based collaboration with Biomia, giving us the opportunity to leverage our broad expertise in drug discovery for CNS disorders. The ISP platform has proven its ability for discovery of entirely novel drug candidates with blockbuster potential across CNS disorders. Biomia’s unique strategy for lead identification and innovative synthesis of compounds makes a good match with our discovery platform,” said Kristina Torfgård, CEO of IRLAB.

 

Under the partnership, IRLAB will apply its ML/AI-supported ISP platform to provide detailed phenotypic characterization and evaluation of Biomia’s small-molecule compounds. 

 

The platform will assess novel compounds, predict potential target indications, and evaluate differentiation from existing treatments across several undisclosed CNS disorders. Biomia will supply the compounds and fund the studies conducted by IRLAB.

 

This collaboration signals a strategic push for both companies to accelerate the discovery of potentially groundbreaking therapies for central nervous system conditions.